What is the recommended tapering schedule for a patient taking alprazolam (Xanax) 1 mg twice daily?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 26, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Alprazolam Taper Protocol

For a patient taking alprazolam 1 mg twice daily (2 mg total daily dose), reduce the dose by 0.25 mg every 1-2 weeks, which represents approximately a 12.5% reduction per step, continuing this gradual taper until complete discontinuation. 1

Initial Taper Strategy

  • Start by reducing the total daily dose by 0.25 mg every 1-2 weeks, which is the FDA-recommended approach for alprazolam discontinuation 2
  • This translates to either:
    • Reducing one dose from 1 mg to 0.75 mg while maintaining the other at 1 mg, OR
    • Reducing both doses proportionally (e.g., 0.875 mg twice daily)
  • The 0.25 mg reduction every 1-2 weeks is specifically recommended for alprazolam regardless of whether this is considered low-dose or high-dose withdrawal 3

Critical Safety Considerations

Abrupt discontinuation must be avoided as benzodiazepine withdrawal can cause rebound anxiety, hallucinations, seizures, delirium tremens, and rarely death 1

  • Alprazolam is particularly problematic for discontinuation compared to other benzodiazepines, with high rates of withdrawal symptoms and rebound phenomena 4
  • The FDA explicitly warns that "abrupt discontinuation of treatment should be avoided" and emphasizes gradual dose reduction 2

Expected Timeline

  • Total taper duration: approximately 8-16 weeks for a 2 mg daily dose using the 0.25 mg every 1-2 week schedule 2
  • Some patients may require an even slower reduction rate, particularly if withdrawal symptoms emerge 2
  • The taper schedule should be slowed or paused if significant withdrawal symptoms develop 1

Managing Withdrawal Symptoms

Adjuvant medications should be used liberally to prevent and treat withdrawal symptoms 1:

  • Clonidine (start low, titrate carefully due to hypotension risk) or tizanidine (less effective but safer blood pressure profile) to directly attenuate withdrawal 1
  • Lofexidine is FDA-approved specifically for opioid withdrawal but principles apply 1
  • For anxiety, insomnia, and irritability: gabapentin, trazodone, mirtazapine, or tricyclic antidepressants for short-term use 1
  • For gastrointestinal symptoms: loperamide (use cautiously, can be abused) 1

Withdrawal Symptom Profile

Common alprazolam withdrawal symptoms include 5, 6:

  • Anxiety, tremor, shaking
  • Nausea/vomiting
  • Insomnia/nightmares
  • Excessive sweating
  • Tachycardia/palpitations
  • Headache, muscle aches, weakness
  • Unique to alprazolam: confusion, clouded sensorium, heightened sensory perception, paresthesias, blurred vision 6

Alternative Approach: Slower Taper

If the patient has been on alprazolam for prolonged periods or experiences significant withdrawal, consider an even more gradual approach:

  • Reduce by 10% of the current dose every 1-2 weeks rather than fixed 0.25 mg decrements 1
  • This means each new dose is 90% of the previous dose, not a straight-line reduction 1
  • For a 2 mg daily dose: 2 mg → 1.8 mg → 1.62 mg → 1.46 mg, etc.
  • This approach may take several months but reduces withdrawal severity 1

Monitoring and Support

  • Close observation during taper is critical with clinician availability to treat symptoms and manage patient fears 1
  • Reassess at each dose reduction for withdrawal symptoms, anxiety levels, and functional status 2
  • Cognitive Behavioral Therapy (CBT) significantly increases tapering success rates and should be offered concurrently 1
  • If benzodiazepines were prescribed for anxiety, evidence-based psychotherapy and/or antidepressants should be offered as alternatives 1

Important Caveats

  • Do not abruptly stop or make large dose reductions except in extreme circumstances like confirmed diversion 1
  • The final dose reductions (below 0.5 mg daily) may be the most difficult and require slower tapering 2, 6
  • Rebound panic attacks occurred in 27% and withdrawal syndrome in 35% of patients in controlled studies, typically peaking at the end of taper 6
  • Some patients may experience protracted withdrawal symptoms (dysphoria, insomnia, anhedonia) for months after complete discontinuation 1

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Detoxification from benzodiazepines: schedules and strategies.

Journal of substance abuse treatment, 1991

Guideline

Alprazolam for Panic Attacks: Clinical Use and Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Discontinuation reactions to alprazolam in panic disorder.

Journal of psychiatric research, 1993

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.